Endogenous oxytocin levels are associated with the perception of emotion in dynamic body expressions in schizophrenia

Schizophrenia Research

Volumn 162, Issue 1-3, 2015, Pages 52-56

  Strauss, Gregory P ^a   Keller, William R ^b   Koenig, James I ^b   Sullivan, Sara K ^a   Gold, James M ^b   Buchanan, Robert W ^b  

^a BINGHAMTON UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Emotion; Emotion perception; Oxytocin; Psychosis; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; OXYTOCIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; EMOTION; FEMALE; GESTURE; HEBEPHRENIA; HUMAN; MALE; NEGATIVE SYNDROME; OXYTOCIN BLOOD LEVEL; POSITIVE SYNDROME; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SEX; TASK PERFORMANCE; BLOOD; FACIAL EXPRESSION; MOVEMENT PERCEPTION; PERCEPTION; PHOTOSTIMULATION; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SEXUAL DEVELOPMENT;

ADULT; EMOTIONS; FACIAL EXPRESSION; FEMALE; GESTURES; HUMANS; MALE; MOTION PERCEPTION; OXYTOCIN; PHOTIC STIMULATION; PSYCHIATRIC STATUS RATING SCALES; PSYCHOLOGICAL TESTS; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX CHARACTERISTICS; SOCIAL PERCEPTION;

EID: 84923217808     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.01.022     Document Type: Article

References (27)

1. Atkinson A.P., Dittrich W.H., Gemmell A.J., Young A.W. Emotion perception from dynamic and static body expressions in point-light and full-light displays. Perception 2004, 33:717-746.
2. Averbeck B.B., Bobin T., Evans S., Shergill S.S. Emotion recognition and oxytocin in patients with schizophrenia. Psychol. Med. 2012, 42(2):259-266.
3. Carter C.S., Pournajafi-Nazarloo H., Kramer K.M., Ziegler T.E., White-Traut R., Bello D., Schwertz D. Oxytocin: behavioral associations and potential as a salivary biomarker. Ann. NY Acad. Sci. 2007, 1098:312-322.
4. Davis M.C., Lee J., Horan W.P., Clarke A.D., McGee M.R., Green M.F., Marder S.R. Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr. Res. 2013, 147(2-3):393-397.
5. Davis M.C., Green M.F., Lee J., Horan W.P., Senturk D., Clarke A.D., Marder S.R. Oxytocin-augmented social cognitive skills training in schizophrenia. Neuropsychopharmacology 2014, 39(9):2070-2077.
6. Domes G., Heinrichs M., Glascher J., Buchel C., Braus D.F., Herpertz S.C. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol. Psychiatry 2007, 62(10):1187-1190.
7. Domes G., Lischke A., Berger C., Grossman A., Hauenstein K., Heinrichs M., Herpertz S.C. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2010, 35(1):83-93.
8. Edwards J., Jackson H.J., Pattison P.E. Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clin. Psychol. Rev. 2002, 22:789-832.
9. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structural Clinical Interview for DSM-IV Axis 1 Disorders (SCID-IV) 1997, New York State Psychiatric Institute, Biometrics Research, New York.
10. Fischer-Shofty M., Brune M., Ebert A., Shefet D., Levkovitz Y., Shamay-Tsoory S.G. Improving social perception in schizophrenia: the role of oxytocin. Schizophr. Res. 2013, 146(1-3):357-362.
11. Gibson C.M., Penn D.L., Smedley K.L., Leserman J., Elliott T., Pedersen C.A. A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophr. Res. 2014, 156(2-3):261-265.
12. Goldman M.B., Gomes A.M., Carter C.S., Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology 2011, 216(1):101-110.
13. Hawk A.B., Carpenter W.T., Strauss J.S. Diagnostic criteria and five-year outcome in schizophrenia. A report from the International Pilot Study of Schizophrenia. Arch. Gen. Psychiatry 1975, 32:343-347.
14. Kirkpatrick B., Strauss G.P., Ngyuen L., Fischer B.A., Daniel D.G., Cienfuegos A., Marder S.R. The Brief Negative Symptom Scale: psychometric properties. Schizophr. Bull. 2011, 37:300-305.
15. Kiss A., Bundzikova J., Pirnik Z., Mikkelsen J.D. Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry. J. Neurosci. Res. 2010, 88(3):677-685.
16. Kohler C.G., Walker J.B., Martin E.A., Healey K.M., Moberg P.J. Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr. Bull. 2010, 36(5):1009-1019.
17. Mendrek A., Mancini-Marie A., Fahim C., Stip E. Sex differences in the cerebral function associated with processing of aversive stimuli by schizophrenia patients. Aust. N. Z. J. Psychiatry 2007, 41(2):136-141.
18. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 1962, 10:799-812.
19. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog L.F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr. Res. 2011, 132(1):50-53.
20. Pfohl B.M., Blum N., Zimmerman M. Structured Interview for DSM-IV Personality 1997, American Psychiatric Publishing, Inc. 1st ed.
21. Razzoli M., Cushing B.S., Carter C.S., Valsecchi P. Hormonal regulation of agonistic and affiliative behavior in female Mongolian gerbils (Meriones unguiculatus). Horm. Behav. 2003, 43(5):549-553.
22. Rubin L.H., Carter C.S., Drogos L., Jamadar R., Pournajafi-Nazarloo H., Sweeney J.A., Maki P.M. Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia. Schizophr. Res. 2011, 130(1-3):266-270.
23. Strauss G.P., Hong L.E., Gold J.M., Buchanan R.W., McMahon R.P., Keller W.R., Fischer B.A., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Factor structure of the Brief Negative Symptom Scale. Schizophr. Res. 2012, 142:96-98.
24. Strauss G.P., Keller W.R., Buchanan R.W., Gold J.M., Fischer B.A., McMahon R.P., Catalano L.T., Culbreth A.J., Carpenter W.T., Kirkpatrick B. Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale. Schizophr. Res. 2012, 142:88-92.
25. Strauss G.P., Keller W.R., Koenig J.I., Gold J.M., Buchanan R.W. Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia. Schizophr. Res. 2015, 162:57-61.
26. Van den Stock J., de Jong S.J., Hodiamont P.P.G., de Gelder B. Perceiving emotions from bodily expressions and multisensory integration of emotion cues in schizophrenia. Soc. Neurosci. 2011, 6(5-6):537-547.
27. Woolley J.D., Chuang B., Lam O., Lai W., O'Donovan A., Rankin K.P., Mathalon D.H., Vinogradov S. Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology 2014, 47:116-125.